ATE368738T1 - Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen - Google Patents

Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen

Info

Publication number
ATE368738T1
ATE368738T1 AT97201105T AT97201105T ATE368738T1 AT E368738 T1 ATE368738 T1 AT E368738T1 AT 97201105 T AT97201105 T AT 97201105T AT 97201105 T AT97201105 T AT 97201105T AT E368738 T1 ATE368738 T1 AT E368738T1
Authority
AT
Austria
Prior art keywords
met
antibody
hgf
extracellular domain
antibody fragment
Prior art date
Application number
AT97201105T
Other languages
English (en)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE368738T1 publication Critical patent/ATE368738T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97201105T 1992-09-18 1993-09-15 Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen ATE368738T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18

Publications (1)

Publication Number Publication Date
ATE368738T1 true ATE368738T1 (de) 2007-08-15

Family

ID=25483898

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93921471T ATE160585T1 (de) 1992-09-18 1993-09-15 Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
AT97201105T ATE368738T1 (de) 1992-09-18 1993-09-15 Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93921471T ATE160585T1 (de) 1992-09-18 1993-09-15 Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie

Country Status (10)

Country Link
EP (2) EP0662130B1 (de)
JP (2) JP3553936B2 (de)
AT (2) ATE160585T1 (de)
AU (1) AU675968B2 (de)
CA (1) CA2144856A1 (de)
DE (2) DE69315440T2 (de)
DK (1) DK0662130T3 (de)
ES (1) ES2112997T3 (de)
GR (1) GR3026165T3 (de)
WO (1) WO1994006909A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0661993B1 (de) * 1992-09-16 1997-05-07 Genentech, Inc. Schutz gegen leberschäden mit hgf
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
CA2270867A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
WO2000025727A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
AU7785401A (en) * 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
CA2532027C (en) 2003-07-18 2016-06-14 Amgen Inc. Specific binding agents to hepatocyte growth factor
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
US7737115B2 (en) 2005-04-15 2010-06-15 Genetech, Inc. HGF beta chain variants
WO2007119447A1 (ja) * 2006-03-20 2007-10-25 Seikagaku Corporation 関節リウマチの処置剤
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
KR102059663B1 (ko) 2010-03-10 2019-12-26 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
CA2832113C (en) 2011-04-02 2020-07-21 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
ATE256736T1 (de) * 1990-09-14 2004-01-15 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JPH07508420A (ja) * 1992-05-18 1995-09-21 ジェネンテク，インコーポレイテッド 肝細胞成長因子変異体

Also Published As

Publication number Publication date
AU675968B2 (en) 1997-02-27
EP0662130A1 (de) 1995-07-12
DK0662130T3 (da) 1998-08-10
GR3026165T3 (en) 1998-05-29
CA2144856A1 (en) 1994-03-31
AU4855593A (en) 1994-04-12
DE69315440D1 (de) 1998-01-08
WO1994006909A3 (en) 1994-05-26
JP3553936B2 (ja) 2004-08-11
DE69315440T2 (de) 1998-07-09
EP0805203A1 (de) 1997-11-05
JPH08504093A (ja) 1996-05-07
WO1994006909A2 (en) 1994-03-31
DE69334159D1 (de) 2007-09-13
JP2004002440A (ja) 2004-01-08
ES2112997T3 (es) 1998-04-16
ATE160585T1 (de) 1997-12-15
EP0662130B1 (de) 1997-11-26
EP0805203B1 (de) 2007-08-01

Similar Documents

Publication Publication Date Title
DE69334159D1 (de) Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen
DK1294769T3 (da) Antistoffer der immunspecifikt binder til BLyS
DE69433406D1 (de) Antikörper gegen cd40
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
BG101024A (bg) Моноклонално антитяло срещу сd44v6
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
DE68927671D1 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
ATE236271T1 (de) Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
DE69002325D1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DE69112717D1 (de) Neue Verwendung von Modafinil.
IL168058A (en) Antibody preferentially linked to cell Ca125 / 0722p relative to ca125 / 0722p deciduous cell, the pharmaceutical composition containing it and its use in the preparation of a drug
BR9707819A (pt) Imunogenos peptidicos
DE69328928D1 (de) Varianten in den leltin domäne von selektin
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69314234D1 (de) Konservierte Polysiloxanemulsion zur Behandlung von Geweben
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69006221D1 (de) Verfahren zur behandlung von septischem schock.
IE821855L (en) Glycerophosphocholines
NO955172L (no) Delesjonsvarianter av protein S med manglende C4BP-bindingsaktivitet, men med APC-kofaktoraktivitet, samt materiale og terapeutiske metoder
EA199800821A1 (ru) Способ лечения аутизма
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties